GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

BACKGROUND: Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Rheumatol
Autores principales: De Luca, Giacomo, Cavalli, Giulio, Campochiaro, Corrado, Della-Torre, Emanuel, Angelillo, Piera, Tomelleri, Alessandro, Boffini, Nicola, Tentori, Stefano, Mette, Francesca, Farina, Nicola, Rovere-Querini, Patrizia, Ruggeri, Annalisa, D'Aliberti, Teresa, Scarpellini, Paolo, Landoni, Giovanni, De Cobelli, Francesco, Paolini, John F, Zangrillo, Alberto, Tresoldi, Moreno, Trapnell, Bruce C, Ciceri, Fabio, Dagna, Lorenzo
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7430344/
https://ncbi.nlm.nih.gov/pubmed/32835256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2665-9913(20)30170-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares